Stoke Therapeutics (STOK) Capital Expenditures (2018 - 2026)
Stoke Therapeutics' quarterly Capital Expenditures came in at $334000.0 in Q1 2026, up 119.74% year-on-year from $152000.0 in Q1 2025, and up 659.09% quarter-over-quarter from $44000.0 in Q4 2025.
Stoke Therapeutics has reported Capital Expenditures for 9 years, with the latest figure at $334000.0 in Q1 2026.
- For the quarter ending Q1 2026, Capital Expenditures rose 119.74% year-over-year to $334000.0; the trailing twelve-month figure through Mar 2026 stood at $664000.0 (up 220.77% YoY), and the FY2025 full-year result was $482000.0, up 690.16% from the prior year.
- Capital Expenditures for Q1 2026 stood at $334000.0, up from $44000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $3.6 million in Q4 2022, with the low at -$1.1 million in Q3 2022.
- Average Capital Expenditures over 5 years is $379705.9, with a median of $229000.0 recorded in 2023.
- Peak annual rise in Capital Expenditures reached 2433.33% in 2025, while the deepest fall reached 1583.33% in 2025.
- Tracing STOK's Capital Expenditures over 5 years: stood at $3.6 million in 2022, then plunged by 93.56% to $229000.0 in 2023, then plunged by 143.67% to -$100000.0 in 2024, then surged by 144.0% to $44000.0 in 2025, then soared by 659.09% to $334000.0 in 2026.
- The last three Capital Expenditures figures came in at $334000.0 (Q1 2026), $44000.0 (Q4 2025), and $387000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 334,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 334,000.00 |
| Mar 31, 2026 | 334,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Sep 30, 2025 | 387,000.00 |
| Jun 30, 2025 | -101,000.00 |
| Jun 30, 2025 | -101,000.00 |
| Mar 31, 2025 | 152,000.00 |
| Mar 31, 2025 | 152,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Dec 31, 2024 | -100,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Sep 30, 2024 | 161,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Mar 31, 2024 | 6,000.00 |
| Dec 31, 2023 | 229,000.00 |
| Dec 31, 2023 | 229,000.00 |
| Sep 30, 2023 | 383,000.00 |
| Sep 30, 2023 | 383,000.00 |
| Jun 30, 2023 | 459,000.00 |
| Jun 30, 2023 | 459,000.00 |
| Mar 31, 2023 | 545,000.00 |
| Mar 31, 2023 | 545,000.00 |
| Dec 31, 2022 | 3.56 Mn |
| Dec 31, 2022 | 3.56 Mn |
| Sep 30, 2022 | -1.12 Mn |
| Sep 30, 2022 | -1.12 Mn |
| Jun 30, 2022 | 682,000.00 |
| Jun 30, 2022 | 682,000.00 |
| Mar 31, 2022 | 841,000.00 |
| Mar 31, 2022 | 841,000.00 |
| Dec 31, 2021 | 1.16 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Sep 30, 2021 | -686,000.00 |
| Sep 30, 2021 | -686,000.00 |
| Jun 30, 2021 | 520,000.00 |
| Jun 30, 2021 | 520,000.00 |
| Mar 31, 2021 | 204,000.00 |
| Mar 31, 2021 | 204,000.00 |
| Dec 31, 2020 | -954,000.00 |
| Dec 31, 2020 | -954,000.00 |
| Sep 30, 2020 | 920,000.00 |
| Sep 30, 2020 | 920,000.00 |
| Jun 30, 2020 | -570,000.00 |
| Jun 30, 2020 | -570,000.00 |
| Mar 31, 2020 | 610,000.00 |
| Mar 31, 2020 | 610,000.00 |
| Dec 31, 2019 | -927,000.00 |
| Dec 31, 2019 | -927,000.00 |
| Sep 30, 2019 | 831,000.00 |
| Sep 30, 2019 | 831,000.00 |
| Jun 30, 2019 | 144,000.00 |
| Jun 30, 2019 | 144,000.00 |
| Mar 31, 2019 | 92,000.00 |
| Mar 31, 2019 | 92,000.00 |
| Dec 31, 2018 | -823,000.00 |
| Dec 31, 2018 | -823,000.00 |
| Sep 30, 2018 | 751,000.00 |
| Sep 30, 2018 | 751,000.00 |